Serologic evidence for early SARS-CoV-2 circulation in Lima, Peru, 2020. 1

2

Andres Moreira-Soto^{*1,2}, Maria Paquita García^{3*}, Gloria Arotinco-Garayar³, Dana 3 Figueroa-Romero³, Nancy Merino-Sarmiento³, Adolfo Marcelo-Ñique³, Edward 4 Málaga-Trillo⁴, César Cabezas Sanchez³ and Jan Felix Drexler^{1,5#} 5

6

- ¹Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, 7
- Humboldt-Universität zu Berlin, Institute of Virology, Berlin, Germany 8
- ²Tropical Disease Research Program, School of Veterinary Medicine, Universidad 9
- 10 Nacional, Costa Rica, Costa Rica
- ³National Institute of Health–INS (Instituto Nacional de Salud–INS), Lima, Peru 11
- ⁴Universidad Peruana Cayetano Heredia, Facultad de Ciencias y Filosofía, 12
- 13 Laboratorios de Investigación y Desarrollo, Lima, Perú
- ⁵German Centre for Infection Research (DZIF), associated partner Charité-14
- Universitätsmedizin Berlin, Berlin, Germany 15
- *These first authors contributed equally 16
- #corresponding author 17
- Correspondence: Professor Dr. Jan Felix Drexler, Institute of Virology, Charitéplatz 1, 18
- 10117 Berlin, Germany, Tel.: +49 30 450 625461/Fax: +49 30 450 7525907, 19
- felix.drexler@charite.de 20
- 21

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

- 22 Running Title:
- 23 Dissemination of SARS-CoV-2 in Peru, early 2020

24

- 25 Keywords:
- 26 SARS-CoV-2, COVID-19, Peru, pandemic, Latin America, serology, antibodies
- 27

28 Abstract

During early 2021, Peru had the highest COVID-19-associated per-capita mortality 29 rate globally. Socioeconomic inequality and insufficiently prepared healthcare and 30 surveillance systems likely contributed to high mortality, potentially coupled with early 31 SARS-CoV-2 introduction. We tested 1,441 individuals with fever sampled during 32 August 2019-May 2021 in Lima, Peru, for SARS-CoV-2-specific antibodies. Serologic 33 testing included a chemiluminescence immunoassay and confirmatory surrogate 34 virus neutralization testing. Early positive samples (n=24) from January-March 2020 35 were further tested using a plaque-reduction neutralization and avidity tests based on 36 SARS-CoV-2 spike and nucleoprotein antigens. None of the early samples were 37 38 PRNT-confirmed, in contrast to 81.8% (18/22) of a subsample from April 2020 onwards (Fischer-exact test, p<0.0001). SARS-CoV-2 antibody detection rate was 39 40 0.9% in mid-April 2020 (1/104; 95% confidence interval (CI), 0.1-5.8%), suggesting 41 onset of viral circulation in early-mid March 2020, consistent with the first molecular detection of SARS-CoV-2 in Peru on March 6th. Mean avidity increase of 62-77% to 42 43 81-94% from all PRNT-confirmed samples during early 2020, were consistent with 44 onset of SARS-CoV-2 circulation during late February/March 2020. Early circulation 45 of SARS-CoV-2 was confirmed in a Susceptible, Exposed, Infected and Recovered mathematical model that projected an effective reproduction number >1, during 46 47 February-March 2020. Robust serologic testing thus confirmed that early SARS-CoV-48 2 introduction contributed to high COVID-19 mortality in Peru. Emphasizing the role of diagnostic confirmation, our study highlights the importance of early detection and 49 accurate testing in managing infectious disease outbreaks. 50

51

53 **Importance**

Latin America was hard hit by the COVID-19 pandemic. Reasons include inadequate 54 healthcare preparation and socio-economic vulnerabilities, likely exacerbated by 55 early undetected SARS-CoV-2 circulation. Diagnostic testing for early SARS-CoV-2 56 57 circulation requires exhaustive diagnostic validation due to unspecific reactivity. We used a cohort of circa 1400 febrile patients from August 2019 until May 2021, months 58 earlier than the first seroprevalence study in Lima, Peru, using a two-step diagnostic 59 algorithm. Early 2020 positive samples were further tested with neutralization tests 60 and avidity testing. We confirmed SARS-CoV-2-specific antibodies from April 2020 61 onwards, suggesting undetected viral circulation circa March 2020, consistent with 62 the first SARS-CoV-2-detection. Early circulation was further confirmed by the 63 significant increase in avidity in positive samples during early 2020 and the modeled 64 peak of reproduction number of >1 during February-March 2020. Using exhaustive 65 diagnostic validation, we detected early SARS-CoV-2 circulation that likely 66 67 contributed to the severe impact of COVID-19 in Peru.

The first cases of COVID-19 were detected in China in mid-December 2019, followed 69 by detections elsewhere in Asia and North America during January 2020 and in 70 Europe during February 2020 (1). The first COVID-19 case in Latin America was 71 detected in Brazil on February 26th, 2020 (1). Despite hosting only 8.5% of the 72 world's population, Latin America accounted for 30% of COVID-19 deaths worldwide 73 (2). Within Latin America, Peru had the highest per-capita mortality rate both 74 regionally and globally (1, 3). Tentative explanations for the high Peruvian mortality 75 rate have included poorly prepared healthcare systems, genetic predisposition, 76 comorbidities, social inequality and poverty, difficulties following quarantine 77 measures, frequent informal labour, and lack of surveillance systems leading to 78 79 inaccurate mortality estimates (4). Early SARS-CoV-2 circulation might be a contributing factor to high mortality in Peru. 80

We investigated SARS-CoV-2-specific IgG antibodies in 1,441 individuals with acute 81 febrile illness investigated between August 2019-May 2021 in the capital city of Lima 82 83 (Figure 1A) by the Peruvian reference laboratory, allowing retrospective analyses several months prior to the first seroprevalence study available from Lima conducted 84 April 2020 (5). The subpopulation consisted of 49.8% females and 50.1% males, with 85 a mean age of 33.7 years and a standard deviation of 20.3 years, comparable to 86 census data from Lima (48.6% males and 51.4% females; mean age=26) 87 (https://censo2017.inei.gob.pe/). 88

Approximately 50% of Peruvian seroprevalence studies have a high risk of bias due 89 to the use of potentially non-specific diagnostic tests affected by co-circulating 90 pathogens such as dengue virus (DENV) and Plasmodium (Figure 1B) (5-7). For 91 confirmation, we used a 2-step testing algorithm including a chemiluminescence 92 immunoassay (CLIA) (SARS-CoV-2 S-RBD IgG kit; Snibe Diagnostic, China), and 93 confirmatory SARS-CoV-2 surrogate virus neutralization test (sVNT; GenScript, 94 USA), both based on the partial SARS-CoV-2 receptor binding domain. Only samples 95 positive in both assays were considered for further analyses to maximize specificity. 96 Additionally, all positive sera from the first six months of 2020, a confirmatory plaque 97 reduction neutralization test (PRNT) based on a 50% reduction in plaque count was 98 performed at 1/8 serum dilution to allow detection of potentially low antibody titers (6). 99 To differentiate between recent and pre-existing SARS-CoV-2 infections, the 100 antibody-antigen binding affinity of SARS-CoV-2 IgG antibodies was determined by 101

conducting an avidity assay using SARS-CoV-2 spike (S1)- and nucleoprotein (NCP) based IgG ELISAs (Euroimmun, Germany) with an additional 2M urea washing step
between sample incubation and detection in one of the replicates.

Several seropositive individuals (n=24) in both CLIA and sVNT were found as early 105 106 as January-March 2020 (Figure 1C and 1D). These samples showed significantly lower CLIA and sVNT reactivity in comparison to samples from April 2020 onward 107 (CLIA t-test=-6.4, p<0.001; sVNT t-test=-10.9, p<0.001) (Figure 1C and 1D). 108 Additionally, these samples showed a statistically higher mean S-based avidity of 109 126.4% and lower NCP-based avidity of 11.0% compared to samples from April 2020 110 onward (S t-test=2.4, p=0.01; NCP t-test=-2.9, p=0.007; Figure 1E and 1F). High 111 avidity to the S protein is reached 1-2 months after SARS-CoV-2 infection and is 112 maintained for approximately 6-8 months (8, 9). High S-based avidity would thus 113 suggest very early SARS-CoV-2 infection in patients sampled during January 2020. 114 contrasting with calculated SARS-CoV-2 phylogenetic introduction estimates and the 115 first SARS-CoV-2 molecular detections in Latin America dating from February 2020 116 onwards (10). Since PRNT is the serological gold-standard, we further tested all 117 SARS-CoV-2 seropositive samples from January-July 2020 (n=46) using PRNT. 118 None of the early samples from January-March 2020 were PRNT-confirmed, in 119 contrast to 81.8% (18/22) samples from April onwards (Fischer-exact test, p<0.0001). 120 However, a study that tested thousands of convalescent plasma samples using 121 PRNT found that nearly one-third of confirmed SARS-CoV-2 patients that resolved 122 infection had little to no neutralizing activity (11), regardless of when the samples 123 were taken after their COVID-19 infection. Therefore, we cannot exclude that the 124 125 PRNT-negative (n=5) CLIA, sVNT and S- NCP-high avidity patients in January-March 2020 might have had a past SARS-CoV-2 infection (Figure 1G). Of note, no sera that 126 127 were CLIA positive in 2019 were sVNT positive, suggesting that a minimum 2-step testing algorithm is needed for accurate SARS-CoV-2 serological diagnostics. As a 128 conservative approach, we decided to exclude non-PRNT confirmed samples from 129 January-March 2020 from subsequent analyses, because unspecific reactivity in 130 CLIA and sVNT in those samples seemed the most plausible explanation. 131

Following diagnostic validation, the SARS-CoV-2 antibody detection rate was 0.9% during April 2020 (1/104; 95% confidence interval (CI), 0.1-5.8%). SARS-CoV-2 antibody detection steadily increased reaching 9.7% (9/93; 95% CI: 5.0-17.8%) in

May 2020, reaching a mean of 35% (148/460; 95% CI: 28.0-36.6%) from June 135 afterwards. Given that the mean detection time of SARS-CoV-2-specific IgG 136 antibodies post-symptom onset is 20 days (13), a projected time of infection for the 137 first PRNT-confirmed case could have occurred in early-middle March 2020 which is 138 consistent with the first molecular detection of SARS-CoV-2 in Peru on March 6th 139 (12), 2020 and genomic reconstructions of SARS-CoV-2 in Latin America (10). 140 Avidity to the SARS-CoV-2 NCP and S protein in all PRNT-confirmed CLIA- and 141 sVNT-positive samples from April to July 2020 was high and increased from a mean 142 77 to 94% for NCP and from 62 to 81% for the S protein by June/July 2020 (NCP t-143 test=-0.66; p= 0.53; S t-test=-1.12; p= 0.29; Figure 1E and 1F). Those avidity results 144 were thus consistent with onset of SARS-CoV-2 circulation during late 145 February/March 2020. 146

Onset of SARS-CoV-2 circulation during February/March in Peru was also in 147 concordance with the increase in reported excess mortality peaking mid-March 2020 148 149 (Figure 2A and 2B). Stagnation of antibody detection rate during mid-2020 in our study was likely due to the strict non-pharmaceutical interventions (NPIs) in place 150 since March 2020 and mounted population immunity after a high infection peak 151 (Figure 2B) (14). Limited transmission is supported by a gradual decline in CLIA 152 titers due to gradual decay of SARS-CoV-2 antibodies (15) during 2020 followed by a 153 resurgence in early 2021 (Figure 1D), potentially due to the emergence of antigenic 154 variants such as gamma during early 2021 (1). Notably, resurgence of CLIA titers 155 paralleled an increase in excess mortality and reported COVID-19 cases during early 156 2021 (Figure 2A). 157

Early viral circulation, stagnation, and resurgence of SARS-CoV-2 infections during 158 early 2021 was confirmed using a Susceptible, Exposed, Infected and Recovered 159 Bayesian model relying on reported cases and antibody detection data from our 160 study (16). The model suggested peak virus circulation, with an effective reproduction 161 number (Reff) >1, during February-March 2020, one to two months before the 162 reported peak incidence and mortality which is plausible given the delay in onset of 163 diagnostics estimated at up to 5 days even in affluent settings (16). The model also 164 reconstructed the decrease in virus circulation after July 2020 and increase during 165 end of 2020 (Figure 2C and 2D). 166

167 Our data suggest undetected onset of SARS-CoV-2 circulation in Lima during 168 February-March 2020 homologous to other hard-hit Latin American COVID-19 hot 169 spots; e.g., Brazil and Ecuador (1, 2). Considering the intense connectivity between 170 Europe, USA and Peru, it is likely that SARS-CoV-2 circulated before the first case 171 was officially reported.

Limitations of our study include the analysis of a cohort that is not representative of the general population. However, the unique cohort allowed to retrospectively trace SARS-CoV-2 over time during the onset of the pandemic. Another limitation is analysis of sera from febrile individuals whose acute disease may affect serologic diagnostics of SARS-CoV-2, including Malaria and dengue (6, 7). However, our exhaustive serologic analyses allowed robust detection of SARS-CoV-2-specific antibodies.

Our study suggests that early introduction and substantial circulation likely exacerbated the high COVID-19 associated mortality observed in Peru, irrespective of other effect modifiers. Our work emphasizes the complex SARS-CoV-2 serologic diagnostic confirmation in tropical settings, crucial in understanding the pandemic's trajectory, and highlights the importance of early detection and accurate testing in managing infectious disease outbreaks.

185

186 Acknowledgments

The code to reproduce the analyses is found in the online repository: 187 XXXXXXXXXXXXX. We thank José Encinas Marroquin, Sebastian Brünink, Arne 188 189 Kühne and Antje Kamprad. This work was funded by the German federal ministry for economic cooperation and development (BMZ) via the Deutsche Gesellschaft für 190 Internationale Zusammenarbeit (GIZ) GmbH (project number 81262528). The 191 procedures were carried out with the approval of the institutional bioethics committee 192 under the ethic protocol number 6528 from VIA LIBRE and EA2/031/22 from Charité-193 Universitaetsmedizin Berlin. 194

195

196 **References:**

medRxiv preprint doi: https://doi.org/10.1101/2024.02.13.24301472; this version posted February 14, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

197 1. Mathieu E, Ritchie H, Rodés-Guirao L, Appel C, Giattino C, Hasell J, et al. Coronavirus 198 Pandemic (COVID-19). Our World in Data. 2020. 199 2. Burki T. COVID-19 in Latin America. Lancet Infect Dis. 2020 May;20(5):547-8. 200 3. Lima EEC, Vilela EA, Peralta A, Rocha M, Queiroz BL, Gonzaga MR, et al. Investigating regional excess mortality during 2020 COVID-19 pandemic in selected Latin American countries. Genus. 201 202 2021;77(1):30. 203 4. Taylor L. Covid-19: Why Peru suffers from one of the highest excess death rates in the world. 204 BMJ. 2021 Mar 9;372:n611. 205 Arora RK, Joseph A, Van Wyk J, Rocco S, Atmaja A, May E, et al. SeroTracker: a global SARS-5. 206 CoV-2 seroprevalence dashboard. Lancet Infect Dis. 2021 Apr;21(4):e75-e6. 207 6. Yadouleton A, Sander AL, Moreira-Soto A, Tchibozo C, Hounkanrin G, Badou Y, et al. Limited 208 Specificity of Serologic Tests for SARS-CoV-2 Antibody Detection, Benin. Emerg Infect Dis. 2021 209 Jan;27(1):233-7. 210 7. Lustig Y, Keler S, Kolodny R, Ben-Tal N, Atias-Varon D, Shlush E, et al. Potential Antigenic 211 Cross-reactivity Between Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and 212 Dengue Viruses. Clin Infect Dis. 2021 Oct 5;73(7):e2444-e9. 213 Takahashi E, Sawabuchi T, Homma T, Fukuda Y, Sagara H, Kinjo T, et al. Clinical Utility of 8. 214 SARS-CoV-2 Antibody Titer Multiplied by Binding Avidity of Receptor-Binding Domain (RBD) in 215 Monitoring Protective Immunity and Clinical Severity. Viruses. 2023 Jul 30;15(8). 216 9. Scheiblauer H, Nübling CM, Wolf T, Khodamoradi Y, Bellinghausen C, Sonntagbauer M, et al. 217 Antibody response to SARS-CoV-2 for more than one year - kinetics and persistence of detection are 218 predominantly determined by avidity progression and test design. J Clin Virol. 2022 Jan;146:105052. 219 Candido DS, Claro IM, de Jesus JG, Souza WM, Moreira FRR, Dellicour S, et al. Evolution and 10. 220 epidemic spread of SARS-CoV-2 in Brazil. Science. 2020 Sep 4;369(6508):1255-60. 221 11. Zhang S, Ma P, Orzechowski M, Lemmer A, Rzasa K, Bagnall J, et al. High-Throughput 222 Neutralization and Serology Assays Reveal Correlated but Highly Variable Humoral Immune 223 Responses in a Large Population of Individuals Infected with SARS-CoV-2 in the US between March 224 and August 2020. mBio. 2023 Apr 25;14(2):e0352322. 225 12. Hou H, Wang T, Zhang B, Luo Y, Mao L, Wang F, et al. Detection of IgM and IgG antibodies in 226 patients with coronavirus disease 2019. Clin Transl Immunology. 2020 May;9(5):e01136. 227 Munayco CV, Tariq A, Rothenberg R, Soto-Cabezas GG, Reyes MF, Valle A, et al. Early 13. 228 transmission dynamics of COVID-19 in a southern hemisphere setting: Lima-Peru: February 29th-229 March 30th, 2020. Infectious Disease Modelling. 2020 2020/01/01/;5:338-45. 230 14. Moreira-Soto A, Bruno A, de Mora D, Paez M, Garces J, Wulf B, et al. Virological evidence of 231 the impact of non-pharmaceutical interventions against COVID-19 in Ecuador, a resource-limited 232 setting. Emerg Microbes Infect. 2023 Dec;12(2):2259001. 233 15. Vabret N. Antibody responses to SARS-CoV-2 short-lived. Nat Rev Immunol. 2020 234 Sep;20(9):519. 235 16. Netto EM, Moreira-Soto A, Pedroso C, Höser C, Funk S, Kucharski AJ, et al. High Zika Virus 236 Seroprevalence in Salvador, Northeastern Brazil Limits the Potential for Further Outbreaks. mBio. 237 2017 Nov 14;8(6). 238 17. Harris JE. Timely epidemic monitoring in the presence of reporting delays: anticipating the 239 COVID-19 surge in New York City, September 2020. BMC Public Health. 2022 2022/05/02;22(1):871.

medRxiv preprint doi: https://doi.org/10.1101/2024.02.13.24301472; this version posted February 14, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in





Figure 1. SARS-CoV-2 seroprevalence studies in Peru and diagnostic 241 confirmation. A) Map that shows Peruvian regions where seroprevalence studies 242 have been performed. Data taken from (serotracker.com). B) Seroprevalence studies 243 in Peru, size shows the risk of bias calculated by serotracker, lines connecting the 244 dots show the total study time. C) Reactivity of serum samples to SARS-CoV-2 in a 245 SARS-CoV-2 surrogate virus neutralization test (sVNT), shown in the x axis, and a 246 chemiluminescence immunoassay (CLIA), shown in the y axis. AU/ml, absorbance 247 unit per milliliter. Triangles show early samples that were positive in a plaque 248 reduction neutralization test (PRNT), Big circles show samples that were negative in 249

medRxiv preprint doi: https://doi.org/10.1101/2024.02.13.24301472; this version posted February 14, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

PRNT. D) CLIA concentration across time in the tested samples. The red line 250 denotes the mean CLIA concentration per month. Gray lines denote the 95% 251 confidence interval. Triangles show early samples that were positive in a plaque 252 reduction neutralization test (PRNT). Big circles show samples that were negative in 253 PRNT, AU/ml; absorbance units per millilitre. E) IgG antibody avidity index against 254 SARS-CoV-2 S and NCP antibodies overtime in PRNT-positive and negative early 255 2020 samples. Horizontal line denotes the index thresholds of >60% (positive) and 256 <40% (negative) results between these values are considered borderline, as defined 257 by the manufacturer (https://www.euroimmun.com). Gray area denotes the 95% 258 confidence interval. F) Boxplots showing the median avidity by a bar, quartiles by 259 boxes, and minimum and maximum by whiskers. Above, p values of a t-test. G) 260 Reactivity of six serum samples that were SARS-CoV-2 PRNT-negative but SARS-261 CoV-2 sVNT and CLIA positive, defined as >30 and >1 respectively, as per 262 manufacturer's instructions. IgG antibody avidity index against SARS-CoV-2 S and 263 NCP antibodies overtime shown in the figure axis, index thresholds of >60% are 264 considered positive as per manufacturer's instructions. 265

266

267

medRxiv preprint doi: https://doi.org/10.1101/2024.02.13.24301472; this version posted February 14, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .



270 excess mortality. The line shows the monthly reported excess mortality during the 271 period. Mortality 272 study data taken from: https://www.datosabiertos.gob.pe/dataset/fallecidos-por-covid-19-ministerio-de-salud-273

minsa-. B) Monthly seropositivity from Lima from this study (dots), gray area 274 represents the 95% confidence interval. Linear regression line is shown in red. C) 275 SEIR model showing the reported incidence data (red dots) and the modeled 276 incidence (gray area) calculated using the reported incidence data and antibody 277 detection rate from this studv. Weekly incidence data taken from 278 (https://www.datosabiertos.gob.pe/dataset/casos-positivos-por-covid-19-ministerio-279

<u>de-salud-minsa</u>). The black line denotes the median modeled incidence, and the gray
area denotes the 1st and 3rd quartiles of the modeled incidence. D) Effective
reproductive number calculated using the model.

283